Who is sponsoring NCT04456023?

NCT04456023 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT04456023?

Interventions in NCT04456023: Tisagenlecleucel.

What condition does NCT04456023 study?

NCT04456023 studies Diffuse Large B-Cell Lymphoma (DLBCL).

Is NCT04456023 still recruiting?

NCT04456023 is currently withdrawn. Last updated 2 March 2022.

Last reviewed 2022-03-02 · How we verify

NCT04456023

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Withdrawn Phase 2 Last updated 2 March 2022

What this trial tests

Phase 2 trial testing Tisagenlecleucel in Diffuse Large B-Cell Lymphoma (DLBCL). Withdrawn.

Timeline

31 January 2022

Primary endpoint
31 October 2022

27 September 2027

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	31 January 2022
Primary completion	31 October 2022
Estimated completion	27 September 2027

Drugs / interventions tested

Tisagenlecleucel (TISAGENLECLEUCEL) — full drug profile →

Conditions studied

Diffuse Large B-Cell Lymphoma (DLBCL) — all drugs for Diffuse Large B-Cell Lymphoma (DLBCL) →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Diffuse Large B-Cell Lymphoma (DLBCL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, phase II study to evaluate the efficacy and safety of CTL019 in Chinese adult patients with relapsed or refractory DLBCL.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

CAR-T cell therapy for cancer: current challenges and future directions.
Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, et al · · 2025 · cited 81× · PMID 40610404 · DOI 10.1038/s41392-025-02269-w
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, et al · · 2021 · cited 36× · PMID 34515338 · DOI 10.1002/14651858.cd013365.pub2

Verify or expand the search:

Other trials of Tisagenlecleucel

Trials testing the same drug.

NCT06785818 — Long-term Follow up Local Registry Study of Kymriah in South Korea · recruiting
NCT05888493 — A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphom · Phase 3 · active not recruiting
NCT05633615 — Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · Phase 2 · recruiting
NCT04890236 — Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell L · EARLY_PHASE1 · completed
NCT04156659 — Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL · Phase 2 · withdrawn

Other recruiting trials for Diffuse Large B-Cell Lymphoma (DLBCL)

Currently open trials in the same condition.

NCT07493109 — Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP · Phase 3 · recruiting
NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting
NCT07397832 — CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL · Phase 2 · recruiting
NCT07499271 — Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation · Phase 2 · recruiting
NCT07189065 — A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma · Phase 2 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04456023 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 2 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04456023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing